Department of Clinical and Molecular Medicine, Sapienza University, 00189 Rome, Italy.
Paediatric Cardiology and ACHD Unit, S. Orsola, Malpighi Hospital, 40138 Bologna, Italy.
Biomolecules. 2021 Mar 2;11(3):376. doi: 10.3390/biom11030376.
The usefulness of cardiopulmonary exercise test (CPET) in adult hypertrophic cardiomyopathy (HCM) patients is well-known, whereas its role in pediatric HCM patients has not yet been explored. The present study investigates possible insights from a CPET assessment in a cohort of pediatric HCM outpatients in terms of functional and prognostic assessment. Sixty consecutive pediatric HCM outpatients aged <18 years old were enrolled, each of them undergoing a full clinical assessment including a CPET; a group of 60 healthy subjects served as controls. A unique composite end-point of heart failure (HF) related and sudden cardiac death (SCD) or SCD-equivalent events was also explored. During a median follow-up of 53 months (25th-75th: 13-84 months), a total of 13 HF- and 7 SCD-related first events were collected. Compared to controls, HCM patients showed an impaired functional capacity with most of them showing peak oxygen uptake (pVO) values of <80% of the predicted, clearly discrepant with functional New York Heart Association class assessment. The composite end-point occurred more frequently in patients with the worst CPETs' profiles. At the univariate analysis, pVO% was the variable with the strongest association with adverse events at follow-up (C-index = 0.72, = 0.025) and a cut-off value equal to 60% was the most accurate in identifying those patients at the highest risk. In a pediatric HCM subset, the CPET assessment allows a true functional capacity estimation and it might be helpful in identifying early those patients at high risk of events.
心肺运动试验(CPET)在成人肥厚型心肌病(HCM)患者中的应用价值已得到广泛认可,但其在儿科 HCM 患者中的作用尚未得到充分探索。本研究旨在探讨 CPET 评估在儿科 HCM 门诊患者中的功能和预后评估方面可能具有的作用。
连续纳入 60 例年龄<18 岁的儿科 HCM 门诊患者,每位患者均接受全面的临床评估,包括 CPET;同时纳入 60 例健康对照者。还探索了心力衰竭(HF)相关和心源性猝死(SCD)或 SCD 等效事件的独特复合终点。
在中位随访 53 个月(25-75%:13-84 个月)期间,共收集到 13 例 HF 相关和 7 例 SCD 相关的首发事件。与对照组相比,HCM 患者的功能能力受损,其中大多数患者的峰值摄氧量(pVO)值<预测值的 80%,与纽约心脏协会(NYHA)功能分级明显不符。复合终点在 CPET 结果最差的患者中更常见。
在单因素分析中,pVO%是与随访时不良事件相关性最强的变量(C 指数=0.72,p=0.025),60%的截断值是识别风险最高患者的最准确值。在儿科 HCM 亚组中,CPET 评估可准确评估患者的实际功能能力,有助于早期识别高风险患者。